A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer|Adjuvant Therapy|HER2-positive Breast Cancer
Sponsor: Pierre Fabre Medicament
Collaborators: Iqvia Pty Ltd